Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a … Read more
Polaryx Therapeutics, Inc. Common Stock (PLYX) - Net Assets
Latest net assets as of September 2025: $5.30 Million USD
Based on the latest financial reports, Polaryx Therapeutics, Inc. Common Stock (PLYX) has net assets worth $5.30 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.98 Million) and total liabilities ($682.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.30 Million |
| % of Total Assets | 88.6% |
| Annual Growth Rate | 268.0% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Polaryx Therapeutics, Inc. Common Stock - Net Assets Trend (2023–2024)
This chart illustrates how Polaryx Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Polaryx Therapeutics, Inc. Common Stock (2023–2024)
The table below shows the annual net assets of Polaryx Therapeutics, Inc. Common Stock from 2023 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.71 Million | +268.99% |
| 2023-12-31 | $1.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Polaryx Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3035600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $16.00K | 0.34% |
| Other Components | $95.35 Million | 2023.47% |
| Total Equity | $4.71 Million | 100.00% |
Polaryx Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Polaryx Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Black Sea Property PLC Ordinary Shares
TA:BSP
|
$54.45K |
|
Ceylon Tobacco Company PLC
CM:CTCN0000
|
$54.47K |
|
CJ Bioscience Inc.
KO:311690
|
$54.51K |
|
GEPA3F
SA:GEPA3F
|
$54.56K |
|
UTIMES ORD A (SHH) EQSW Exp:
SHG:688638
|
$54.39K |
|
Edri-El
TA:EDRL
|
$54.38K |
|
AMG Acquisition Corp
V:AMG-P
|
$54.31K |
|
XTC Lithium Limited
AU:XTC
|
$54.27K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Polaryx Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,277,000 to 4,712,000, a change of 3,435,000 (269.0%).
- Net loss of 30,356,000 reduced equity.
- New share issuances of 7,320,000 increased equity.
- Other factors increased equity by 26,471,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-30.36 Million | -644.23% |
| Share Issuances | $7.32 Million | +155.35% |
| Other Changes | $26.47 Million | +561.78% |
| Total Change | $- | 268.99% |
Book Value vs Market Value Analysis
This analysis compares Polaryx Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 226.27x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 834.90x to 226.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $0.01 | $5.63 | x |
| 2024-12-31 | $0.02 | $5.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Polaryx Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -644.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.06x
- Recent ROE (-644.23%) is below the historical average (-470.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | -295.93% | 0.00% | 0.00x | 1.81x | $-3.91 Million |
| 2024 | -644.23% | 0.00% | 0.00x | 1.06x | $-30.83 Million |
Industry Comparison
This section compares Polaryx Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Polaryx Therapeutics, Inc. Common Stock (PLYX) | $5.30 Million | -295.93% | 0.13x | $54.44K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |